By admin 
CureSearch for Children’s Cancer, a leading national nonprofit foundation dedicated to ending childhood cancer by driving targeted and innovative research, has formally announced the appointment of Osama Alsaleh to its Board of Directors. This strategic addition comes at a pivotal moment for the organization as it seeks to bridge the gap between laboratory breakthroughs and clinical applications. Alsaleh, a distinguished healthcare leader with a multifaceted background in venture capital, health equity, and global technology, brings a unique set of skills designed to address the systemic funding and innovation challenges that have historically hindered progress in the field of pediatric oncology. By integrating his extensive network within the global startup ecosystem and his experience in large-scale healthcare IT, CureSearch aims to catalyze the development of new and more effective treatments for the thousands of children diagnosed with cancer each year.
A Career Defined by Global Health Innovation and Strategic Leadership
Osama Alsaleh’s professional trajectory reflects a deep commitment to transforming healthcare through technology and strategic partnerships. Currently serving as the Head of Partnerships at Plug and Play Health—a division of Plug and Play Tech Center, the world’s most active venture capital firm and global innovation platform—Alsaleh is at the forefront of identifying and scaling disruptive healthcare solutions. His role involves connecting corporations, startups, and investors to foster an environment where technological advancements can be rapidly deployed to solve pressing medical challenges.
Before joining Plug and Play, Alsaleh held several high-impact roles at Oracle Health (formerly Cerner Corporation), where he was instrumental in shaping the company’s approach to global health and equity. One of his most notable achievements was the creation of Oracle’s health equity team. In this capacity, he developed transformative strategies aimed at addressing the social determinants of health (SDOH), ensuring that technological advancements in healthcare are accessible to underserved populations. His work at Oracle also extended to the financial oversight of healthcare initiatives; as a member of the Oracle Charitable Foundation Clinical Decision Committee, he contributed to the evaluation and strategic allocation of more than $42 million in healthcare grants. This experience provided him with a rigorous understanding of how philanthropic capital can be utilized to drive measurable clinical outcomes.
Beyond the private sector, Alsaleh has been a consistent voice in the public and regulatory spheres. His career includes advisory roles and collaborations with the World Bank Group, the World Health Organization (WHO), and the U.S. State Department. During the height of the global pandemic, he contributed his expertise to the White House COVID-19 Taskforce, assisting in the coordination of data-driven responses to the public health crisis. His familiarity with regulatory compliance and quality reporting measures, particularly concerning Centers for Medicare & Medicaid Services (CMS) initiatives, positions him as a vital link between innovative research and the complex regulatory frameworks required for clinical adoption.
Addressing the Funding Gap in Pediatric Oncology
The appointment of Alsaleh to the CureSearch board is specifically designed to address a long-standing disparity in the medical research landscape. Despite cancer being the leading cause of death by disease among children in the United States, pediatric oncology research receives significantly less funding and attention than adult oncology. According to data from the National Cancer Institute (NCI), only about 4% of the federal budget for cancer research is dedicated specifically to childhood cancers.
This funding shortfall creates what researchers often call the "Valley of Death"—the period between a laboratory discovery and the start of clinical trials where many promising treatments stall due to a lack of financial support. Because the market for pediatric drugs is smaller than that for adult diseases, traditional pharmaceutical companies and venture capital firms often view these investments as higher risk with lower potential returns.
Alsaleh’s entry into the CureSearch leadership is a direct response to this economic reality. In his official statement, Alsaleh noted that innovations focused on pediatrics remain significantly underrepresented within mainstream venture capital and innovation ecosystems. His goal is to leverage his network to attract new technologies and strategic partners that can provide the necessary resources to move pediatric treatments through the development pipeline. By applying venture capital principles—such as rigorous vetting, milestone-based funding, and strategic scaling—to the nonprofit sector, CureSearch intends to de-risk pediatric research projects, making them more attractive for eventual commercial development.
Chronology of Strategic Growth and Organizational Evolution
The addition of Osama Alsaleh follows a period of significant strategic evolution for CureSearch. Founded with a mission to support clinical trials and laboratory research, the organization has increasingly shifted its focus toward "venture philanthropy." This model emphasizes the importance of not just funding research, but actively managing the path to commercialization to ensure that discoveries actually reach the bedside.
- 2010–2015: CureSearch began refining its focus toward high-impact, high-potential research projects, moving away from broad-spectrum funding to a more targeted "Catapult" program designed to accelerate drug development.
- 2016–2020: The organization expanded its reach by forming the CureSearch Industry Advisory Council (IAC), bringing together leaders from the pharmaceutical and biotech industries to provide expert guidance on which research projects have the highest likelihood of clinical success.
- 2021–2023: Recognizing the role of data and health equity, CureSearch began integrating social determinants of health into its research criteria, ensuring that new treatments are effective across diverse patient populations.
- 2024: The appointment of Osama Alsaleh signals a new chapter where venture capital expertise and global technology partnerships become central to the organization’s strategy.
Official Responses and Strategic Vision
The leadership at CureSearch has expressed high expectations for the impact Alsaleh will have on the foundation’s future. Jared Brancazio, Chair of the CureSearch Board of Directors, emphasized that Alsaleh’s unique perspective is exactly what the organization needs at this juncture. "Osama’s ability to connect innovation, investment, and healthcare will help expand our reach and unlock new opportunities to advance critical research for children with cancer," Brancazio stated. "We are excited to have him join the board at this important time for our organization."
For Alsaleh, the role is a natural extension of his career-long advocacy for sustainable and equitable healthcare solutions. He intends to use his position to bridge the gap between the startup world and the nonprofit research sector. By convening leaders across healthcare, technology, and investment, he aims to create a more robust support system for pediatric oncologists and researchers who are working on the next generation of therapies, such as CAR-T cell innovations, targeted genomic treatments, and precision medicine.
Broader Impact and Implications for the Pediatric Research Landscape
The implications of bringing a venture capital and health equity expert into the fold of a major pediatric cancer nonprofit are significant. First, it suggests a shift in how nonprofits view their role in the drug development lifecycle. Rather than acting solely as donors, organizations like CureSearch are increasingly acting as "accelerators," providing the strategic oversight and networking capabilities usually reserved for the private sector.
Second, Alsaleh’s background in health equity is likely to influence how CureSearch selects and funds research. In the United States, disparities in access to clinical trials and specialized pediatric care often result in poorer outcomes for minority and low-income children. By applying a health equity lens to the research portfolio, Alsaleh can help ensure that the "better treatments" CureSearch promises are accessible to all children, regardless of their socioeconomic status or geographic location.
Finally, the involvement of a leader from Plug and Play Health signals to the broader investment community that pediatric oncology is a field ripe for technological disruption. With the rise of artificial intelligence in drug discovery and the increasing use of big data in clinical trials, the expertise Alsaleh brings regarding healthcare IT and global health initiatives will be invaluable in modernizing the way pediatric cancer research is conducted and shared across borders.
As CureSearch continues to navigate the complexities of the modern medical landscape, the appointment of Osama Alsaleh serves as a testament to the organization’s commitment to innovation. By combining the heart of a philanthropic mission with the strategic rigor of venture capital and global technology, CureSearch is positioning itself to make meaningful, lasting progress in the fight against childhood cancer, ultimately bringing more effective and less toxic treatments to the children who need them most.
